TRIMTECH Therapeutics, a biotechnology company pioneering small molecule therapeutics that selectively degrade protein aggregates to combat neurodegenerative diseases, has appointed Dr. Mike Hutton to its Scientific Advisory Board (SAB). According to the TRIMTECH Therapeutics press release, Dr. Hutton will provide strategic scientific guidance to advance the company’s targeted protein degradation (TPD) programs, including its TRIMTAC™ and TRIMGLUE™ pipelines focused on Alzheimer’s and Parkinson’s disease.
Dr. Hutton Brings Over 30 Years of Groundbreaking Experience
Dr. Hutton has accumulated more than three decades of experience in neurodegenerative disease research and drug development. He previously served as Chief Scientific Officer and Vice President of Neurodegeneration Research as well as UK Site Scientific Leader at Eli Lilly and Company, where he directed discovery programs for Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia.
Before his tenure at Eli Lilly, Dr. Hutton held senior roles at MSD and served as a Consultant and Professor of Neuroscience at the Mayo Clinic. While at Mayo, his team made pivotal contributions by identifying the genetic causes of frontotemporal dementia, including mutations in tau and progranulin. His groundbreaking work on tau earned him both the Potamkin Prize and the MetLife Prize. Dr. Hutton holds a BSc in Biochemistry from the University of Manchester and a PhD in Neuroscience from the University of Cambridge.
Leadership Welcomes the Appointment
Dr. Nicola Thompson, CEO of TRIMTECH Therapeutics, expressed her enthusiasm about the appointment:
“We’re delighted to welcome Mike as the newest member of our recently formed Scientific Advisory Board. His extensive expertise in neurodegenerative disease therapeutics will be a great asset as we continue advancing our mission to deliver first-in-class medicines. Our goal remains clear — to develop cost-effective, disease-modifying treatments for neurodegeneration that can reach broad patient populations.”
Dr. Hutton’s Vision for the Future
Sharing his excitement, Dr. Hutton stated:
“TRIMTECH’s novel approach is redefining how we tackle neurological disorders. By developing small molecule CNS-penetrant degraders, the company is addressing the difficult-to-drug targets at the heart of these diseases. I’m thrilled to join such a talented SAB and look forward to guiding the development of these much-needed, accessible therapeutic options.”